Literature DB >> 20949775

Association of severity of COPD with IgE and interleukin-1 beta.

B Singh1, S Arora, V Khanna.   

Abstract

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a pulmonary inflammatory disease characterised by airflow limitation. The role of various inflammatory mediators such as interleukin-1beta (IL-beta) and Immunoglobulin E (IgE) have been implicated in COPD. In present study we aimed to establish if there is an association between the serum levels of IL-1beta and IgE and the severity of airway obstruction.
MATERIALS AND METHODS: The study group comprised of 30 non atopic smokers, suffering from COPD and 30 non smoker, healthy controls. Serum levels of IgE and IL-1beta were assayed by ELISA in all subjects along with their pulmonary function tests.
RESULTS: Serum IgE and IL-1beta levels were significantly raised in COPD patients as compared to healthy controls. IL-1beta was negatively correlated with FEV1 (r = -0.624, p = 0.003) and IgE showed a negative correlation with FVC (r = -0.477, p = 0.034).
CONCLUSION: Our study suggests that in COPD IL-1beta and IgE serum levels correlate with clinical aspects of disease severity. We suggest that the production of IgE and IL-1beta in the airways of patients with COPD may be related to smoking which affects airway obstruction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20949775     DOI: 10.4081/monaldi.2010.303

Source DB:  PubMed          Journal:  Monaldi Arch Chest Dis        ISSN: 1122-0643


  19 in total

1.  Membrane microdomains regulate NLRP10- and NLRP12-dependent signalling in A549 cells challenged with cigarette smoke extract.

Authors:  Dhirendra P Singh; Gagandeep Kaur; Prathyusha Bagam; Rakeysha Pinkston; Sanjay Batra
Journal:  Arch Toxicol       Date:  2018-04-06       Impact factor: 5.153

2.  A critical role for dendritic cells in the evolution of IL-1β-mediated murine airway disease.

Authors:  Mitsuo Hashimoto; Haruhiko Yanagisawa; Shunsuke Minagawa; Debasish Sen; Amanda Goodsell; Royce Ma; Catherine Moermans; Kate J McKnelly; Jody L Baron; Matthew F Krummel; Stephen L Nishimura
Journal:  J Immunol       Date:  2015-03-18       Impact factor: 5.422

3.  Treatment with intranasal iloprost reduces disease manifestations in a murine model of previously established COPD.

Authors:  Matthew R Lammi; Mohamed A Ghonim; Kusma Pyakurel; Amarjit S Naura; Salome V Ibba; Christian J Davis; Samuel C Okpechi; Kyle I Happel; Bennett P deBoisblanc; Judd Shellito; A Hamid Boulares
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-02-05       Impact factor: 5.464

Review 4.  Lung Dendritic Cells: Shaping Immune Responses throughout Chronic Obstructive Pulmonary Disease Progression.

Authors:  Christine M Freeman; Jeffrey L Curtis
Journal:  Am J Respir Cell Mol Biol       Date:  2017-02       Impact factor: 6.914

5.  Interleukin-1beta induces increased transcriptional activation of the transforming growth factor-beta-activating integrin subunit beta8 through altering chromatin architecture.

Authors:  Jennifer A Markovics; Jun Araya; Stephanie Cambier; Sangeeta Somanath; Stephanie Gline; David Jablons; Arthur Hill; Paul J Wolters; Stephen L Nishimura
Journal:  J Biol Chem       Date:  2011-08-30       Impact factor: 5.157

6.  Transforming Growth Factor-β and Interleukin-1β Signaling Pathways Converge on the Chemokine CCL20 Promoter.

Authors:  Oliver J Brand; Sangeeta Somanath; Catherine Moermans; Haruhiko Yanagisawa; Mitsuo Hashimoto; Stephanie Cambier; Jennifer Markovics; Andrew J Bondesson; Arthur Hill; David Jablons; Paul Wolters; Jianlong Lou; James D Marks; Jody L Baron; Stephen L Nishimura
Journal:  J Biol Chem       Date:  2015-04-27       Impact factor: 5.157

7.  TLR9 expression is required for the development of cigarette smoke-induced emphysema in mice.

Authors:  Robert F Foronjy; Matthias A Salathe; Abdoulaye J Dabo; Nathalie Baumlin; Neville Cummins; Edward Eden; Patrick Geraghty
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-06-10       Impact factor: 5.464

Review 8.  Inflammation and immune response in COPD: where do we stand?

Authors:  Nikoletta Rovina; Antonia Koutsoukou; Nikolaos G Koulouris
Journal:  Mediators Inflamm       Date:  2013-07-15       Impact factor: 4.711

Review 9.  Musculoskeletal disorders in chronic obstructive pulmonary disease.

Authors:  Nele Cielen; Karen Maes; Ghislaine Gayan-Ramirez
Journal:  Biomed Res Int       Date:  2014-03-25       Impact factor: 3.411

Review 10.  Chronic obstructive pulmonary disease.

Authors:  V K Vijayan
Journal:  Indian J Med Res       Date:  2013-02       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.